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ABSTRACT
Objectives: Risk assessment is an important part of
emergency patient care. Risk assessment tools based
on biochemical data have the advantage that
calculation can be automated and results can be easily
provided. However, to be used clinically, existing tools
have to be validated by independent researchers. This
study involved an independent external validation of
four risk stratification systems predicting death that rely
primarily on biochemical variables.
Design: Prospective observational study.
Setting: The medical admission unit at a regional
teaching hospital in Denmark.
Participants: Of 5894 adult (age 15 or above) acutely
admitted medical patients, 205 (3.5%) died during
admission and 46 died (0.8%) within one calendar day.
Interventions: None.
Main outcome measures: The main outcome
measure was the ability to identify patients at an
increased risk of dying (discriminatory power) as area
under the receiver-operating characteristic curve
(AUROC) and the accuracy of the predicted probability
(calibration) using the Hosmer-Lemeshow goodness-of-
fit test. The endpoint was all-cause mortality, defined in
accordance with the original manuscripts.
Results: Using the original coefficients, all four
systems were excellent at identifying patients at
increased risk (discriminatory power, AUROC ≥0.80).
The accuracy was poor (we could assess calibration for
two systems, which failed). After recalculation of the
coefficients, two systems had improved discriminatory
power and two remained unchanged. Calibration failed
for one system in the validation cohort.
Conclusions: Four biochemical risk stratification
systems can risk-stratify the acutely admitted medical
patients for mortality with excellent discriminatory
power. We could improve the models for use in our
setting by recalculating the risk coefficient for the
chosen variables.
INTRODUCTION
An important part of the routine work of front-
line personnel in emergency departments and
admission units is to assess the risk of individual
patients. However, many physicians feel inad-
equately trained,1 and prognostication is not a
mandatory part of medical education.2 As a con-
sequence, automated risk stratiﬁcation could
assist physicians attending to emergency
patients. However, in a recent review,3 none of
the risk stratiﬁcation tools for use in the emer-
gency departments and admission units attained
the highest level of evidence. Several systems
have been developed, but only a few have been
externally validated, even though this is an
important part of the development process.4
Some of the existing risk stratiﬁcation
systems are based solely on vital signs and
others on biochemical analyses. Systems
ARTICLE SUMMARY
Article focus
▪ Physicians staffing emergency departments and
admission units are not comfortable predicting
the risk of mortality for their patients.
▪ Several systems that can do this have been
developed but not externally validated and
should thus not yet be used in clinical practice.
▪ The aim of this article was to validate four exist-
ing biochemical risk stratification systems pre-
dicting mortality of acutely admitted patients.
Key messages
▪ The four risk prediction systems based on bio-
chemical data are excellent at predicting mortality
of acutely admitted medical patients.
▪ The precision of the predictions is low, but can
be improved by adjusting the systems to the
local environment by recalculating the scores.
Strengths and limitations of this study
▪ This is the largest study to validate biochemical-
based risk stratification systems in a medical
admission unit.
▪ This study has good external validity and a low
risk of selection bias.
▪ The study is limited by missing data especially in
two of the four scores and by the fact that it is a
single centre study.
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based on vital signs require manual collection of data,
whereas systems based on biochemical analyses can be
automated. Data can easily be extracted from the hos-
pital computer systems and risk stratiﬁcation can be per-
formed in an automated process.
We performed the present study with the objective of
validating existing risk stratiﬁcation systems that predict
mortality for medical patients based solely on biochemical
data. Four systems based on multiple (more than two) rou-
tinely available variables (in our setting) and not restricted
to selected groups of medical patients were included.
METHODS
We performed an external validation of existing bio-
chemical risk stratiﬁcation systems by applying the coefﬁ-
cients and ORs reported in the original papers.
Furthermore, we validated the choice of variables in the
original papers by recalculating the coefﬁcients to ﬁt
our current patient population.
Setting
Sydvestjysk Sygehus is a 460-bed regional teaching hos-
pital in the western part of Denmark with a contingency
population of 220 000. All subspecialties of internal
medicine are represented.
Patients can be admitted to the medical admission unit
(MAU) by their general practitioner, out-of-hours emer-
gency medical service, outpatient clinics, emergency
department and ambulance services. Two attending phy-
sicians, one in internal medicine and one in cardiology,
one senior resident and two interns staff the MAU.
Design and data
We conducted a prospective observational cohort study
of all patients admitted through the MAU at our hos-
pital. All consecutive adult patients (ages ≥15 years)
admitted from 2 October 2008 until 19 February 2009
(ﬁrst cohort) and from 23 February 2010 until 26 May
2010 (second cohort) were included in the study.
Upon admission, a nurse recorded the vital signs and
registered these along with demographic information
and the primary complaint on a form. After inclusion of
all patients, we extracted blood test results from the hos-
pital computer systems. No extra biochemical analyses
were added as part of this study, and only analyses
ordered by the admitting doctor were included. Most
patients had the following biochemical standard panel
taken: haemoglobin, leukocytes, platelets, C reactive
protein, sodium, potassium, creatine, urea, total
calcium, glucose and albumin. Almost all patients admit-
ted to the cardiology section had troponin, amylase and
total cholesterol measured as well. We included blood
tests drawn 1 h prior to admission and within 6 h after
admission. If a patient had multiple analyses of the same
biochemical variable, only the ﬁrst was included. In case
of missing data on forms (or completely missing forms),
data were extracted from an electronic copy of the
nurse’s notes or the chart. Inclusion of all patients was
ensured by validation against the central hospital data-
base. As we have no formalised classiﬁcation system for
primary complaints, one of the authors (MB) converted
the primary complaint to a diagnosis according to the
International Statistical Classiﬁcation of Diseases and
Related Health Problems, 10th Revision (ICD-10)5 and
compiled these as admissions due to
▸ Infectious disorders (ICD-10 diagnoses A and B);
▸ Malignancy (ICD-10 diagnoses C and D);
▸ Endocrine disorders (ICD-10 diagnoses E);
▸ Circulatory disorders (ICD-10 diagnoses I);
▸ Pulmonary disorders (ICD-10 diagnoses J);
▸ Symptoms (ICD-10 diagnoses R);
▸ Observational reasons (ICD-10 diagnoses Z);
▸ Other reasons (ICD-10 diagnoses F, G, H, K, L, M, N,
O, P, Q, S, T, X and Y).
We analysed the performance of four different risk
stratiﬁcation systems based on biochemical variables: the
system introduced by Prytherch et al6 required gender,
mode of admission, age, urea, sodium, potassium,
albumin, haemoglobin, white cell count and creatine.
Froom and Shimoni7 included age, albumin, alkaline
phosphatase, aspartate aminotransferase, urea, glucose,
lactate dehydrogenase, neutrophil count proportion and
total leucocyte count. Loekito et al8 required haemoglo-
bin, haematocrit, total CO2, leucocytes, albumin, biliru-
bin, creatine and urea. We estimated haematocrit from
haemoglobin9 and total CO2 from bicarbonate.
10 The
score by Asadollahi et al11 required age, urea, haemoglo-
bin, leucocytes, platelets, sodium and glucose. If the
patient missed one or more of the biochemical variables
required for a given risk assessment tool, the patient was
excluded from the validation of that tool.
We deﬁned the primary outcome as in the original
articles, that is, in-hospital mortality for Prytherch et al6
Asadolliahi et al11 and Froom and Shimoni7 and immi-
nent death (ie, death within one calendar day after the
blood was drawn) for Loekito et al8 Data on this were
extracted from the hospital computer systems after the
inclusion was completed and all patients were either dis-
charged or dead.
The study was approved by the Danish Data Protection
Agency. Approval from an Ethics Committee was not
required according to Danish law. The study is reported
in accordance with the STROBE statement.12
Statistics
The sample size was dictated by another part of the
study. In brief, the sample size was calibrated to develop
and validate a risk-stratiﬁcation system to predict 7-day
all-cause mortality.
We calculated the predicted mortality using the coefﬁ-
cients presented in the original papers. To assess the
ability of each system to identify patients at highest risk
of dying (ie, the discriminatory power), we calculated
the area under the receiver-operating characteristic
curve (AUROC). AUROC is a summary measure of
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sensitivity and speciﬁcity at each possible cut-off and
basically represents the probability that a patient who
eventually dies will have a higher score than a patient
who survives. An AUROC above 0.8 is said to represent
excellent discriminatory power.13 The calibration was
assessed using the Hosmer-Lemeshow goodness-of-ﬁt
test. The calibration assesses if the observed mortality
rate matches the expected rate, derived from the scoring
systems. For this test, we divided the population into
decentiles by expected event rate. A p value above 0.05
indicates acceptable calibration. A scoring system might
show excellent discriminatory power and yet have poor
calibration if, for example, it was developed on a popula-
tion with low overall mortality and then applied to a
population with high overall mortality.
As the predictive power would be expected to vary
across populations, we calculated the AUROC of each of
the original scores for patients presenting with the previ-
ously speciﬁed presenting complaints.
Finally, we attempted to optimise the models to our
setting by recalculating the scoring coefﬁcients; that is,
we performed the multivariable analyses anew by using
the variables included in the original models. We used
the ﬁrst cohort (collected from 2008 to 2009) for the
development and the second cohort (collected in 2010)
for validation of the recalculated coefﬁcients.
As the Asadollahi score11 is a set score (ranging from 0
to 20) and not a regression formula, we initially performed
a new logistic regression using our development cohort.
From the coefﬁcients derived, we assigned a score (from 1
Table 1 Demographics of patients
Total, n=5894 First cohort, n=3046 Second cohort, n=2848
Female 2950 (50.1%) 1460 (47.9%) 1490 (52.3%)
Age (years) 65 (49–77) 66 (50–77) 64 (48–76)
Length of stay (days) 2 (1–6) 2 (1–6) 1 (1–5)
In-hospital mortality 205 (3.5%) 116 (3.8%) 89 (3.1%)
Imminent death 46 (0.8%) 26 (0.9%) 20 (0.7%)
Admitted due to infectious disorder 178 (3.0%) 82 (2.7%) 96 (3.4%)
Admitted due to malignant disorder 128 (2.2%) 50 (1.6%) 78 (2.8%)
Admitted due to endocrine disorder 307 (5.2%) 147 (4.8%) 160 (5.6%)
Admitted due to circulatory disorder 1375 (23.4%) 527 (17.3%) 848 (29.9%)
Admitted due to pulmonary disorder 972 (16.5%) 547 (18.0%) 425 (15.0%)
Admitted due to symptoms 1194 (20.3%) 719 (23.6%) 475 (16.7%)
Admitted due to observation 1012 (17.2%) 585 (19.2%) 427 (15.1%)
Admitted due to other reasons 718 (12.2%) 389 (12.8%) 329 (11.6%)
Table 2 Variables included in the scores and the level of missing data
Variable
Percentage of
missing
Prytherch
score6
Froom
score7
Loekito
score8
Asadollahi
score11
Lactate dehydrogenase 76.6 •
Bilirubin 75.1 •
Alkaline phosphatase 75.0 •
Bicarbonate 71.6 •
Alanine aminotransferase 68.3 •
Neutrophil count
proportion
42.1 •
Urea/creatine 13.0 •
Urea 12.7 • • • •
Albumin 7.5 • • •
Platelets 7.1 •
Glucose 6.9 • •
White cell count 6.0 • • •
Creatine 5.8 • • •
Potassium 5.5 •
Sodium 5.2 • •
Haemoglobin 5.1 • • •
Haematocrit 5.1 •
Age 0.0 • • • •
Gender 0.0 •
Mode of admission 0.0 •
•Required in the score.
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to 6) to each variable and recalculated the score for both
cohorts. We tested calibration according to Seymour
et al,14 that is , we predicted the probabilities of the individ-
ual scores using logistic regression analysis and calculated
the Hosmer-Lemeshow goodness-of-ﬁt test.
Data are reported as median (IQR) or proportions
whenever appropriate. Differences between patients with
and without missing data were tested using the χ2 test or
Wilcoxon rank-sum test.
STATAV.12.1 (StataCorp, College Station, Texas, USA)
was used for the analyses.
RESULTS
A total of 5894 patients were included in our study (see
table 1 for details). Among these, 205 (3.5%) died during
the admission, and 46 (0.8%) died within one calendar day.
Validation of the original scores
We could include 4925 patients (83.6% of the entire
cohort) in the Prytherch score (table 2). Using the ori-
ginal formula, we found an AUROC of 0.842 (95% CI
0.818 to 0.865; ﬁgure 1 and table 3) and goodness-of-ﬁt
test, χ2=419.63 (10 degrees of freedom), p<0.001. Thus,
the Pryterch score showed a good ability to identify
patients at high risk of dying, but failed in calibration, as
fewer patients died than expected.
In calculating the Froom score,7 we could include
only 919 patients (15.6%; table 2). Using the ORs speci-
ﬁed in the original article, we found an AUROC of
0.862 (95% CI 0.813 to 0.910; ﬁgure 1 and table 3). As
the original paper did not provide the coefﬁcient for
the intercept, we were unable to reliably assess calibra-
tion. In an attempt to reduce selection bias, Froom and
Shimoni7 used imputation of the mean (by assigning the
Figure 1 Discriminatory power of four risk stratification systems based on biochemical variables. Original coefficients were used
to generate receiver-operating curves.
Table 3 Performance of the model using the original coefficients and after recalculation
Score
Discriminatory power
(AUROC)
Calibration
(Hosmer-Lemeshow χ2 test p value)
Original model
Recalculated model Original
model
Recalculated model
Development Validation Development Validation
Prytherch
score6
0.842 (0.818–0.865) 0.858 (0.827–0.889) 0.874 (0.841–0.907) <0.001 0.59 0.66
Froom score7 0.862 (0.813–0.910) 0.930 (0.897–0.962) 0.882 (0.806–0.957) − 0.93 0.009
Loekito score8 0.922 (0.879–0.965) 0.911 (0.819–1.000) 0.917 (0.823–1.000) 0.0007 0.79 1.00
Asadollahi
score11
0.803 (0.776–0.829) 0.808 (0.774–0.842) 0.813 (0.772–0.854) − 0.79 0.47
Area under receiver-operating curve (AUROC) above 0.8 represents good discriminatory power, and p value for calibration above 0.05
represents good calibration
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value of 2.5 to all missing variables reduced into quar-
tiles). Adapting this approach led to the inclusion of all
5894 patients with an AUROC of 0.814 (CI 0.788 to
0.841). Again, because of a missing coefﬁcient for the
intercept, we could not assess calibration. Thus, the
Froom score was good at identifying patients at high
risk, but we could not assess the level of precision.
As for the Loekito score,8 we could include 540
patients (9.2%; table 2). Using the reported coefﬁcients,
we found an excellent discriminatory power
(AUROC=0.922, CI 0.879 to 0.965, ﬁgure 1 and table 3).
Calibration failed with a goodness-of-ﬁt test, χ2=30.7,
p=0.0007. Thus, the Loekito score showed excellent dis-
criminatory power but failed calibration.
We could include 4863 (82.5%) in the Asadollahi
score11 (table 2). We found a good calibration
(AUROC=0.803; CI 0.776 to 0.829; ﬁgure 1 and table 3),
but could not assess it because of the construction of
the score in the original article.
The predictive ability of each score varied widely with
each presenting compliant; however, within each com-
plaint, the scores more or less had identical AUROCs
(table 4). Overall, malignant, endocrine and pulmonary
disorders had the lowest AUROC, while infectious
disorders had the highest (table 4). Some of these calcu-
lations are based on limited numbers (as indicated by
the CIs).
Recalculated coefficients
Performing the recalculation of the Prytherch score,6 we
achieved excellent AUROCs in both cohorts as well as
acceptable calibration (ﬁgure 2 and table 3). Sex, urea,
sodium, haemoglobin, creatine and potassium were not
signiﬁcantly associated with in-hospital mortality in our
material, but because they were included in the original,
we kept them in the analysis.
Recalculating the Froom score,7 we achieved excellent
AUROCs in both cohorts, but calibration failed in the
validation cohort (ﬁgure 2 and table 3). Age, alkaline
phosphatase, alanine aminotransferase, urea, white cell
count and glucose were not signiﬁcantly associated with
in-hospital mortality, but were kept in the model.
When recalculating the Loekito score,8 we found that
urea, creatine, albumin, haemoglobin and white cell
count were not signiﬁcantly associated with the endpoint
of 1-day mortality. We achieved excellent AUROCs
in both cohorts as well as almost perfect calibration
(ﬁgure 2 and table 3).
When recalculating the Asadollahi score,11 we
assigned a score of one each to haemoglobin, platelets
and glucose (none of which were signiﬁcantly associated
with the endpoint), three to sodium, four each to age
and white cell count and six to urea. AUROC was excel-
lent in both cohorts and calibration acceptable (ﬁgure 2
and table 3).
In all four methods, the discriminatory power remained
constant or improved when we compared it with the calcu-
lation based on the original coefﬁcients and ORs.
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Selection bias
For the Prytherch, Froom and Asadollahi scores, patients
who were excluded because of missing values had the
same mortality as those who were included (table 5). For
the Loekito score, patients with missing data had signiﬁ-
cantly lower 1-day mortality (table 5).
DISCUSSION
Using four existing biochemical-based risk stratiﬁcation
systems, we could risk-stratify acutely admitted medical
patients with excellent discriminatory power. We could
only evaluate the calibration for two scores, the
Prytherch score6 and the Loekito score,8 which both
failed. When recalculating all four scores, both discrim-
inatory power and calibration improved, except for the
Froom score,7 where calibration failed.
In the present article, we focused only on biochemical-
based risk stratiﬁcation systems. While systems based on
vital signs can be calculated shortly after arrival,
biochemical-based systems require the blood tests to be
analysed ﬁrst. On the other hand, for systems based only
on biochemical data, interobserver or intraobserver vari-
ation is virtually eliminated. We have identiﬁed four
systems with broad inclusion criteria that could poten-
tially be used in emergency departments and MAUs.
The systems included were developed in different set-
tings, ranging from ﬂoor beds6 8 11 to a medical emer-
gency room.7 One was internally validated using a split
sample technique,6 while the others were validated in
external cohorts.7 8 11 However, even if the systems were
developed in a setting similar to ours and validated by
the original authors, they still need to be externally
validated in independent cohorts, as we now have per-
formed, before they should be used in the clinical
routine.4
Although all four systems had acceptable discrimin-
atory power, two systems failed in calibration. One way of
correcting poor calibration is to perform a recalculation.
We have carried out so by performing a multivariable
logistic regression in one cohort and then validating
it in another. This approach generally improved the
discriminatory power and made calibration acceptable.
In fact, calibration became acceptable in both systems
that previously failed. After recalculation, however,
calibration failed in the Froom score,7 a system for
which we could not test calibration using the original
formula. Our best explanation for this is differences in
mortality because the Froom score7 was developed and
validated in cohorts with a higher mortality than ours
(5.6% vs 3.5%).
The Prytherch score6 seems to ﬁt our setting best. The
discriminatory power was excellent both before and
after recalculation. Calibration failed before recalcu-
lation, but was acceptable afterwards. Most important,
using our standard biochemical proﬁle, we could
include the majority of our patients. Both the Froom7
and Loekito scores8 performed better, but only margin-
ally, and the Froom score7 failed on calibration after
recalculation; we could include only a few of our
patients in both scores. However, the choice of score
depends on several additional factors. Some hospitals
might not routinely measure all investigations required
by each score (eg, albumin) and some investigations are
error prone (eg, haemolysis in potassium measure-
ments). The Asadollahi score only relies on seven
Figure 2 Discriminatory power after recalculation of new coefficients to match our setting.
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parameters and could thus be easily obtained and
perhaps less expensive to report on most patients. Also,
it is not signiﬁcantly inferior to the other scores and
might therefore be more suitable for other settings.
Our study has limitations. First, we have a substantial
amount of missing data. This absence is not a major
problem when calculating the Prytherch6 or Asadollahi
score,11 but it was for the Froom7 and Loekito scores.8
There is no doubt that this has introduced selection bias
into our study. Although that we have not been able to
demonstrate any selection bias for the Prytherch, Froom
and Asadollahi scores looking at our primary endpoint
of mortality,6 7 11 we showed that patients with missing
data in the Loekito score8 had a signiﬁcantly lower mor-
tality. An apparent explanation is that bicarbonate is
part of the formula. At our institution, bicarbonate is
mostly analysed as part of arterial blood gas analyses and
thus primarily measured in the most critically ill
patients. Patients with missing data also had a signiﬁ-
cantly shorter length of stay, but were not uniformly
older or younger than patients that could be included in
each score (table 5). These indications of selection
biases prompt us to question the external validity and
generalisability of our ﬁndings, and we see this as an
indication that further studies, where the risk of selec-
tion bias is minimised, are required. Second, the
Loekito score8 requires haematocrit (we estimated this
using the haemoglobin level9) and total CO2 (which we
estimated using bicarbonate).10 However, when perform-
ing our own logistic regression analyses of both systems,
we had acceptable results, proving this to be of no
concern. Third, this study still represents a single centre
application of the scoring systems, and the results
should be evaluated with this in mind. Fourth, we run a
risk of overﬁtting15–17 when performing recalculation.
With only 26 imminent fatalities in the development
cohort, overﬁtting is a potential risk for the Loekito
score.8 However, our validation proves that it was not an
issue. As for the other three systems, we have enough
fatalities for a valid recalculation.
We have found that four risk stratiﬁcation systems
based on biochemical data can identify patients at an
increased risk of dying, although with limited precision.
The models could be improved by recalculation, but the
question remains if the use of these systems will improve
clinical practice. In an ideal study, patients should be
randomised to either be risk-stratiﬁed by a predeﬁned
system or be managed by clinical assessment alone, and
the potential improvement in treatment should be mea-
sured. This approach is a complicated setup not previ-
ously performed for any of the present systems, but is
the only way to show if the implementation of the system
matters.
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